FDA Orange Book · active-ingredient family
Neomycin sulfate; triamcinolone acetonide
Neomycin sulfate; triamcinolone acetonide is approved in 6 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
0
Brand (NDA)
6
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Generic (ANDA) products (6)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| MYTREX A | SAVAGE LABS | ANDA 062598 | — | Jul 21, 1986 | |
| NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE | FOUGERA | ANDA 062600 | — | Jul 21, 1986 | |
| NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE | PHARMADERM | ANDA 062595 | — | Jul 21, 1986 | |
| MYTREX A | SAVAGE LABS | ANDA 062609 | — | May 23, 1986 | |
| NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE | FOUGERA | ANDA 062608 | — | May 23, 1986 | |
| NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE | PHARMADERM | ANDA 062607 | — | May 23, 1986 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Neomycin sulfate; triamcinolone acetonide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
